CA2448425A1 - Inhalation capsules - Google Patents
Inhalation capsules Download PDFInfo
- Publication number
- CA2448425A1 CA2448425A1 CA002448425A CA2448425A CA2448425A1 CA 2448425 A1 CA2448425 A1 CA 2448425A1 CA 002448425 A CA002448425 A CA 002448425A CA 2448425 A CA2448425 A CA 2448425A CA 2448425 A1 CA2448425 A1 CA 2448425A1
- Authority
- CA
- Canada
- Prior art keywords
- capsules
- inhalation according
- capsule material
- inhalation
- moisture content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/003—Particle size control by passing the aerosol trough sieves or filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to inhalation capsules (Inhalettes) made from specific capsule material with reduced moisture content, containing the active agent tiotropium in the form of a powder preparation and characterised by an improved stability.
Claims (16)
1) Capsules for inhalation which contain as the inhalable powder tiotropium in admixture with a physiologically acceptable excipient, characterised in that the capsule material has a reduced moisture content (TEWS or halogen drier moisture content of less than 15%).
2) Capsules for inhalation according to claim 1, characterised in that the capsule material is selected from among gelatine, cellulose derivatives, starch, starch derivatives, chitosan and synthetic plastics.
3) Capsules for inhalation according to claim 2, characterised in that the capsule material used is gelatine in admixture with other additives selected from among polyethyleneglycol (PEG), preferably PEG 3350, glycerol, sorbitol, propyleneglycol, PEO-PPO block copolymers and other polyalcohols and polyethers.
4) Capsules for inhalation according to claim 3, characterised in that the capsule material contains, in addition to gelatine, PEG in an amount of 1-10% (wt.-%), preferably 3-8 %.
5) Capsules for inhalation according to claim 3 or 4, characterised in that the capsule material has a TEWS or halogen drier moisture content of less than 12%, particularly preferably<=10%.
6) Capsules for inhalation according to claim 2, characterised in that the capsule material is selected from the cellulose derivatives hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxymethylcellulose and hydroxyethylcellulose.
7) Capsules for inhalation according to claim 6, characterised in that the capsule material has a TEWS or halogen drier moisture content of less than 8%, particularly preferably<=5%.
8) Capsules for inhalation according to claim 2, characterised in that the capsule material is selected from the synthetic plastics polyethylene, polycarbonate, polyester, polypropylene and polyethylene terephthalate.
9) Capsules for inhalation according to claim 8, characterised in that the capsule material is selected from polyethylene, polycarbonate and polyethylene terephthalate.
10) Capsules for inhalation according to claim 8 or 9, characterised in that the capsule material has a TEWS or halogen drier moisture content of less than 3%, particularly preferably <= 1 %.
11) Capsules for inhalation according to one of claims 1 to 10, characterised in that the inhalable powder contains 0.001 to 2% tiotropium in admixture with a physiologically acceptable excipient.
12) Capsules for inhalation according to claim 11, characterised in that the excipient consists of a mixture of coarser excipient with an average particle size of 15 to 80µm and finer excipient with an average particle size of 1 to 9 µm , the proportion of finer excipient in the total quantity of excipient being 1 to 20%.
13) Capsules for inhalation according to claim 12, characterised in that the tiotropium is in the form of its chloride, bromide, iodide, methanesulphonate, para-toluenesulphonate or methylsulphate.
14) Use of capsules for inhalation according to one of claims 1 to 13 for use in an inhaler which is suitable for administering inhalable powders.
15) Use according to claim 14 for the treatment of asthma or COPD.
16) Use of empty capsules which are characterised by a TEWS or halogen drier moisture content of less than 15%, for preparing tiotropium-containing capsules for inhalation according to one of claims 1 to 13.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10126924.2 | 2001-06-01 | ||
| DE10126924A DE10126924A1 (en) | 2001-06-01 | 2001-06-01 | Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability |
| PCT/EP2002/005600 WO2002098874A2 (en) | 2001-06-01 | 2002-05-27 | Inhalation capsules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2448425A1 true CA2448425A1 (en) | 2002-12-12 |
| CA2448425C CA2448425C (en) | 2010-12-21 |
Family
ID=7687020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2448425A Expired - Fee Related CA2448425C (en) | 2001-06-01 | 2002-05-27 | Inhalation capsules |
Country Status (37)
| Country | Link |
|---|---|
| EP (2) | EP1379220B1 (en) |
| JP (3) | JP4447311B2 (en) |
| KR (2) | KR100921904B1 (en) |
| CN (3) | CN101697965A (en) |
| AR (2) | AR034346A1 (en) |
| AT (1) | ATE285752T1 (en) |
| AU (2) | AU2002344354B2 (en) |
| BG (1) | BG65655B1 (en) |
| BR (1) | BR0209366A (en) |
| CA (1) | CA2448425C (en) |
| CH (1) | CH1379220H1 (en) |
| CO (1) | CO5540379A2 (en) |
| CZ (1) | CZ300284B6 (en) |
| DE (2) | DE10126924A1 (en) |
| EA (1) | EA005188B1 (en) |
| EC (2) | ECSP034868A (en) |
| EE (1) | EE05416B1 (en) |
| EG (1) | EG24227A (en) |
| ES (1) | ES2236590B5 (en) |
| HR (1) | HRP20030993B1 (en) |
| HU (3) | HU230058B1 (en) |
| IL (2) | IL158917A0 (en) |
| ME (1) | ME00301B (en) |
| MX (1) | MXPA03010990A (en) |
| MY (1) | MY126253A (en) |
| NO (1) | NO332857B3 (en) |
| NZ (1) | NZ530356A (en) |
| PE (1) | PE20030071A1 (en) |
| PL (2) | PL203801B1 (en) |
| PT (1) | PT1379220E (en) |
| RS (1) | RS50353B (en) |
| SI (1) | SI1379220T1 (en) |
| SK (2) | SK287379B6 (en) |
| TW (1) | TWI327921B (en) |
| UA (1) | UA75659C2 (en) |
| WO (1) | WO2002098874A2 (en) |
| ZA (1) | ZA200308340B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8281784B2 (en) | 2006-04-11 | 2012-10-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mouthpiece for an inhaler |
| US8875701B2 (en) | 2006-04-11 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Inhaler |
| US8899229B2 (en) | 2005-02-23 | 2014-12-02 | Optinose As | Powder delivery devices |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00245B (en) | 2000-10-12 | 2011-02-10 | Boehringer Ingelheim Int | Novel tiotropium-containing inhalation powder |
| DE10126924A1 (en) * | 2001-06-01 | 2002-12-05 | Boehringer Ingelheim Pharma | Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability |
| DE10212264A1 (en) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Crystalline micronisate, process for its preparation and its use for the manufacture of a medicament |
| JP2005530765A (en) * | 2002-05-07 | 2005-10-13 | ネクター セラピューティクス | Capsules for dry powder inhalers and methods of making and using the same |
| US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
| DE10255387A1 (en) * | 2002-11-28 | 2004-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New tiotropium-containing powder formulation for inhalation |
| DE10258360A1 (en) * | 2002-12-12 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Chamber for accommodation of disposable capsules for powder inhalers has an inner surface with protruding elements serving as distance pieces between the capsules |
| DE10352277A1 (en) * | 2003-11-08 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | powder inhaler |
| SE0303570L (en) | 2003-12-03 | 2005-06-04 | Microdrug Ag | Moisture-sensitive medical product |
| SE0303269L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medical product |
| US7694676B2 (en) | 2005-04-22 | 2010-04-13 | Boehringer Ingelheim Gmbh | Dry powder inhaler |
| JP4825455B2 (en) * | 2005-05-02 | 2011-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Powder inhaler |
| GB0716026D0 (en) | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
| DE102007036411A1 (en) | 2007-07-20 | 2009-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | powder inhaler |
| DE102007052871A1 (en) * | 2007-11-02 | 2009-05-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Capsule for receiving pharmaceutical drug formulations |
| CA2714178A1 (en) * | 2008-02-08 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Method and device for filling capsules |
| EP2172190A1 (en) * | 2008-10-02 | 2010-04-07 | Laboratorios Liconsa, S.A. | Inhalable particles comprising tiotropium |
| PT3578169T (en) | 2009-02-26 | 2024-07-29 | Glaxo Group Ltd | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| WO2010110760A1 (en) * | 2009-03-27 | 2010-09-30 | Mahmut Bilgic | Compositions comprising water with deuterium for the prevention or treatment of allergic diseases and a process for the preparation thereof |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| WO2011152804A2 (en) | 2010-06-03 | 2011-12-08 | Mahmut Bilgic | Process for dry powder formulations |
| DE202011102694U1 (en) | 2011-06-29 | 2011-12-19 | Zisser Gmbh | Inhaler for home users |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| EA036153B1 (en) | 2012-07-05 | 2020-10-06 | Арвен Айлак Санайи Ве Тиджарет А.С. | Pharmaceutical composition for inhalation, packed dosage form, capsule, method of treating obstructive airway diseases and pharmaceutical kit |
| DE202013000774U1 (en) | 2013-01-21 | 2013-04-15 | Rhinofilt GmbH | Miniaturized inhalation device for home use |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| CN108295042A (en) * | 2018-03-05 | 2018-07-20 | 上海祺宇生物科技有限公司 | A kind of plant hollow capsule and its capsule for sucking medicament |
| CN108451920A (en) * | 2018-03-14 | 2018-08-28 | 绍兴康可胶囊有限公司 | A kind of suction mist formula capsule and preparation method thereof |
| CN114848605B (en) * | 2022-03-25 | 2023-08-11 | 上海方予健康医药科技有限公司 | Gelatin capsule for inhalation of powder fog agent |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931041C2 (en) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them |
| WO1993025193A1 (en) * | 1992-06-12 | 1993-12-23 | Teijin Limited | Pharmaceutical preparation for intra-airway administration |
| US6228394B1 (en) * | 1997-10-14 | 2001-05-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Supercritical fluid extraction of mould lubricant from hard shell capsules |
| DE19835346A1 (en) * | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Two-part capsule for pharmaceutical preparations for powder inhalers |
| JP2000143502A (en) * | 1998-11-11 | 2000-05-23 | Shionogi Qualicaps Kk | Inhalant preparation |
| EP2266548B1 (en) * | 1998-11-13 | 2020-05-20 | Jagotec AG | Dry powder for inhalation |
| DE19921693A1 (en) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects |
| EP1072258A1 (en) * | 1999-07-28 | 2001-01-31 | Greither, Peter | Capsule for the release of bacteria, containing lyophilised bacteria and a method for the production thereof |
| CA2387212A1 (en) * | 1999-10-12 | 2001-04-19 | Kaken Pharmaceutical Co., Ltd. | Dry powder inhalation and a method for the preparation thereof |
| DE10126924A1 (en) * | 2001-06-01 | 2002-12-05 | Boehringer Ingelheim Pharma | Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability |
-
2001
- 2001-06-01 DE DE10126924A patent/DE10126924A1/en not_active Withdrawn
-
2002
- 2002-05-27 AT AT02776507T patent/ATE285752T1/en active
- 2002-05-27 EE EEP200300595A patent/EE05416B1/en unknown
- 2002-05-27 SI SI200230077T patent/SI1379220T1/en unknown
- 2002-05-27 HU HU0400666A patent/HU230058B1/en not_active IP Right Cessation
- 2002-05-27 CN CN200910149591A patent/CN101697965A/en active Pending
- 2002-05-27 NZ NZ530356A patent/NZ530356A/en not_active IP Right Cessation
- 2002-05-27 MX MXPA03010990A patent/MXPA03010990A/en active IP Right Grant
- 2002-05-27 HU HU1500188A patent/HU230827B1/en unknown
- 2002-05-27 AU AU2002344354A patent/AU2002344354B2/en not_active Expired
- 2002-05-27 WO PCT/EP2002/005600 patent/WO2002098874A2/en active Application Filing
- 2002-05-27 KR KR1020037015718A patent/KR100921904B1/en active IP Right Grant
- 2002-05-27 ME MEP-2008-425A patent/ME00301B/en unknown
- 2002-05-27 PL PL364108A patent/PL203801B1/en unknown
- 2002-05-27 KR KR1020097000835A patent/KR100952321B1/en active IP Right Review Request
- 2002-05-27 PT PT02776507T patent/PT1379220E/en unknown
- 2002-05-27 CA CA2448425A patent/CA2448425C/en not_active Expired - Fee Related
- 2002-05-27 CN CN201010143914A patent/CN101829072A/en active Pending
- 2002-05-27 CZ CZ20033579A patent/CZ300284B6/en not_active IP Right Cessation
- 2002-05-27 BR BR0209366-9A patent/BR0209366A/en active Pending
- 2002-05-27 PL PL387118A patent/PL205714B1/en unknown
- 2002-05-27 DE DE50201898T patent/DE50201898D1/en not_active Expired - Lifetime
- 2002-05-27 CN CNA028109791A patent/CN1512875A/en active Pending
- 2002-05-27 CH CH02776507T patent/CH1379220H1/de unknown
- 2002-05-27 UA UA20031212504A patent/UA75659C2/en unknown
- 2002-05-27 JP JP2003501995A patent/JP4447311B2/en not_active Expired - Lifetime
- 2002-05-27 EA EA200301275A patent/EA005188B1/en not_active IP Right Cessation
- 2002-05-27 SK SK1620-2003A patent/SK287379B6/en not_active IP Right Cessation
- 2002-05-27 HU HU1800092A patent/HU231082B1/en unknown
- 2002-05-27 EP EP02776507A patent/EP1379220B1/en not_active Expired - Lifetime
- 2002-05-27 ES ES02776507.2T patent/ES2236590B5/en not_active Expired - Lifetime
- 2002-05-27 RS YUP-935/03A patent/RS50353B/en unknown
- 2002-05-27 EP EP04026411A patent/EP1508330A1/en not_active Withdrawn
- 2002-05-27 IL IL15891702A patent/IL158917A0/en unknown
- 2002-05-27 SK SK50049-2009A patent/SK287346B6/en not_active IP Right Cessation
- 2002-05-29 AR ARP020102000A patent/AR034346A1/en not_active Ceased/Invalidation/Refusal/Rejection/Nullification
- 2002-05-29 EG EG20020570A patent/EG24227A/en active
- 2002-05-31 TW TW091111706A patent/TWI327921B/en not_active IP Right Cessation
- 2002-05-31 PE PE2002000465A patent/PE20030071A1/en active IP Right Grant
- 2002-05-31 MY MYPI20022036A patent/MY126253A/en unknown
-
2003
- 2003-10-27 ZA ZA200308340A patent/ZA200308340B/en unknown
- 2003-11-18 IL IL158917A patent/IL158917A/en active IP Right Grant
- 2003-11-24 BG BG108380A patent/BG65655B1/en active Active
- 2003-11-27 EC EC2003004868A patent/ECSP034868A/en unknown
- 2003-11-27 NO NO20035265A patent/NO332857B3/en not_active IP Right Cessation
- 2003-11-28 HR HR20030993A patent/HRP20030993B1/en not_active IP Right Cessation
- 2003-12-10 CO CO03108303A patent/CO5540379A2/en not_active Application Discontinuation
-
2006
- 2006-02-15 JP JP2006038063A patent/JP4787034B2/en not_active Expired - Lifetime
-
2007
- 2007-10-03 JP JP2007260177A patent/JP2008050364A/en active Pending
-
2008
- 2008-07-10 AU AU2008203057A patent/AU2008203057C1/en not_active Expired
-
2011
- 2011-01-06 EC EC2011004868A patent/ECSP11004868A/en unknown
-
2012
- 2012-01-06 AR ARP120100053A patent/AR084804A2/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8899229B2 (en) | 2005-02-23 | 2014-12-02 | Optinose As | Powder delivery devices |
| US11571531B2 (en) | 2005-02-23 | 2023-02-07 | OptiNose Inc. | Powder delivery devices |
| US8281784B2 (en) | 2006-04-11 | 2012-10-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mouthpiece for an inhaler |
| US8875701B2 (en) | 2006-04-11 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Inhaler |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2448425A1 (en) | Inhalation capsules | |
| RU2417224C2 (en) | New crystalline forms of tiotropium bromide | |
| CA2125685C (en) | Powders for inhalation and process for preparing them | |
| AU757008B2 (en) | Novel tiotropium-containing inhalation powder | |
| US7462367B2 (en) | Anticholinergic powder formulations for inhalation | |
| CA2310826A1 (en) | Soft-pellet drug and process for the preparation thereof | |
| KR101313904B1 (en) | Novel crystalline anhydrate with anticholinergic effect | |
| ZA200602343B (en) | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | |
| EP1401409A2 (en) | Stable powder inhalation dosage formulation | |
| JP2019500916A (en) | Blister for inhalation formulation of tiotropium bromide | |
| CA2507579A1 (en) | Pulverulent formulation for inhalation containing tiotropium | |
| EP2804590A1 (en) | Dry powder formulations comprising tiotropium and carmoterol | |
| CA2479919A1 (en) | Powder formulations suitable for inhalation | |
| CA2531832C (en) | Powdery formulations for inhalation, containing a novel anticholinergic agent | |
| KR101748796B1 (en) | Inhalation capsule with enhanced delivery rate of active ingredients | |
| Witek Jr | Anticholinergics: tiotropium | |
| CA2536050A1 (en) | Novel inhalation powder comprising the cgrp antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine | |
| JPH0826996A (en) | Capsule containing codeine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |